Please assess the completion status of the following clinical trial:

Trial Title: Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HbA1C 7.0 % to 10.0% on metformin monotherapy; may be withdrawn from other (non-metformin) drugs if HbA1C is 6.5% to 9.5 % at screening.~Exclusion Criteria:~* Subjects currently treated with a thiazolidinedione are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- colesevelam (Type: EXPERIMENTAL): colesevelam tablets 625 mg
- rosiglitazone (Type: ACTIVE_COMPARATOR): rosiglitazone maleate 4mg
- sitagliptin (Type: ACTIVE_COMPARATOR): sitagliptin phosphate tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).